October 17, 2022

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

October 05, 2022

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

August 24, 2022

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

August 09, 2022

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

August 02, 2022

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

July 05, 2022

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

June 06, 2022

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2022

ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences

May 31, 2022

ChemoCentryx Announces Changes to its Board of Directors

May 18, 2022

ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa

May 16, 2022

ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference

May 11, 2022

ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis

May 05, 2022

ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights

April 28, 2022

ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

April 13, 2022

ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022

March 01, 2022

ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

February 23, 2022

ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022

February 09, 2022

ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

January 19, 2022

ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

January 04, 2022

ChemoCentryx to Present at Two Upcoming Investor Conferences

November 12, 2021

Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)

November 10, 2021

ChemoCentryx to Participate in Two Upcoming Investor Conferences

November 09, 2021

ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights

November 04, 2021

Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)

November 02, 2021

ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021

October 11, 2021

ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer

October 08, 2021

ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis

September 27, 2021

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

September 02, 2021

ChemoCentryx to Participate in Two Upcoming Investor Conferences

August 09, 2021

ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights

August 04, 2021

ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference

August 02, 2021

ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021

July 06, 2021

ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis

June 16, 2021

ChemoCentryx to Participate in the Raymond James 2021 Human Health Innovations Conference

June 08, 2021

ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress

May 06, 2021

ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

April 29, 2021

ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights

April 22, 2021

ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021

April 09, 2021

ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting

April 07, 2021

ChemoCentryx to Host Virtual R&D Day on April 14, 2021

March 08, 2021

ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

March 01, 2021

ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

February 25, 2021

ChemoCentryx to Present at Two Upcoming Investor Conferences

February 24, 2021

ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer

February 23, 2021

ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021

February 17, 2021

ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

January 06, 2021

ChemoCentryx to Participate in Two Upcoming Investor Conferences

December 21, 2020

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

November 19, 2020

ChemoCentryx to Present at Two Upcoming Investor Conferences

November 09, 2020

ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights